BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023

Product Information

The size and complexity of biological medicines, as well as the way they are produced, may result in a degree of natural variability in molecules of the same active substance, particularly in different batches of the medicine. verifying the approved names of all relevant ingredients including ‘non-active’ ingredients (the BNF is committed to using approved names and descriptions as laid down by the Human Medicine Regulations 2012); . g. 6 g daily in 3 divided doses); the total daily dose should be divided into individual doses (in the second example, the patient should receive 2 g 3 times daily). Evidence used to make a recommendation is assessed for validity using standardised methodology tools based on AGREE II or SIGN and then assigned a level of evidence. In addition, the editorial team receives advice on all therapeutic areas from expert clinicians; this ensures that the BNF’s recommendations are relevant to practice.

Guidance on prescribing General guidance Medicines should be prescribed only when they are necessary, and in all cases the benefit of administering the medicine should be considered in relation to the risk involved. This is particularly useful where occasionally, due to differences in therapeutic use, the drug monograph may not directly follow the drug class monograph (e. The sodium content of a medicine is provided in the product literature for all medicines containing  1 mmol sodium per dose; below this level is considered essentially sodium-free. The legal status is shown for prescription-only medicines and controlled drugs, as well as pharmacy medicines and medicines on the general sales list.

Although navigation is possible by browsing, primarily access to the information is via the index, which covers the titles of drug class monographs, drug monographs, and treatment summaries. Drug monographs have also changed structurally: additional sections have been added, ensuring greater regularity around where information is located within the publication.

Now, all of the information for the systemic use of a drug is contained within one monograph, so codeine phosphate p. Read more about the condition New: A new, unread, unused book in perfect condition with no missing or damaged pages. The BNF team works closely with the editorial team that produces Martindale: The Complete Drug Reference. Drug class monographs In earlier editions of the BNF, information relating to a class of drugs sharing the same properties (e.The book cover has no visible wear, and the dust jacket (if applicable) is included for hard covers. Safety monitoring Biosimilar medicines are subject to a black triangle status (A) at the time of initial authorisation. g. ‘125 mg 3 times daily’); terms such as ‘5 mL’ or ‘1 tablet’ should be avoided except for compound preparations. The names of drugs and preparations should be written clearly and not abbreviated, using approved titles only; avoid creating generic titles for modified-release preparations. e. those published before BNF 70): Front matter, comprising information on how to use the BNF, the significant content changes in each edition, and guidance on various prescribing matters (e.

Level 2++ High quality systematic reviews of case control or cohort studies; or high quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal. Once in a chapter, location is guided by the side of the page showing the chapter number (the thumbnail), alongside the chapter title.The only exception is where there is a demonstrable difference in clinical effect between each manufacturer’s version of the formulation, making it important that the patient should always receive the same brand; in such cases, the brand name or the manufacturer should be stated. Prescribing medicines outside the recommendations of their marketing authorisation alters (and probably increases) the prescriber’s professional responsibility and potential liability. Grade B: Moderate strength Guidelines, assessed using AGREE II, that meet the grade B threshold; or a body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+. The 103 third parties who use cookies on this service do so for their purposes of displaying and measuring personalized ads, generating audience insights, and developing and improving products. In the case of compound preparations, the prescribing information for all constituents should be taken into account.